What does the rest of 2018 have in store for biotech?
On Tuesday, we hosted a conference call with STAT Plus subscribers to briefly recap the year so far and chew over some of the major biotech events we’re looking out for in the coming months. That means discussing Celgene’s upcoming cancer data, Sarepta Therapeutics’ future in gene therapy, the gene-editing prospects for Sangamo Therapeutics, and the risks surrounding Esperion Therapeutics’ cholesterol drug. We also touched on Amarin, Global Blood Therapeutics, and the existential crisis facing large-cap biotech companies.
Take a listen and tell us what you think. We’re new to this whole conference call thing, but we’re planning to do more in the future, so we’d love to hear your feedback on potential topics and expert guests. Email us at [email protected] and [email protected].
